[144] Athira Pharma, Inc. SEC Filing

Rhea-AI Filing Summary

Athira Pharma, Inc. (NASDAQ: ATHA) has filed a Form 144, disclosing a proposed sale of 25,123 common shares through Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, on or about 01 Jul 2025. These shares equal roughly 0.06 % of the company’s 39,042,445 shares outstanding.

The shares were acquired on 30 Jun 2025 via a “Restricted Stock Lapse” tied to equity compensation. No other sales by the same insider have occurred in the past three months according to the filing. Aggregate market value is listed as 7,374 (units not specified). The sale will be executed on the NASDAQ exchange.

Because the transaction size is immaterial compared with ATHA’s float and no identity or role of the seller is provided, the filing is generally viewed as routine rather than a signal of strategic or operational change. Form 144 merely gives notice of intent; the sale may or may not ultimately occur. Investors may interpret the filing as normal portfolio or tax management following the vesting of stock-based compensation, rather than a negative assessment of Athira Pharma’s prospects.

Positive

• Sale size is de-minimis at roughly 0.06 % of the 39.0 million shares outstanding, implying limited market impact.
• No other insider sales reported in the prior three months, reducing concerns about a broader sell-off.

Negative

• Insider intent to sell can be interpreted as a potential signal of lower confidence, even if size is small.
• Aggregate market value disclosure (7,374) appears low and lacks unit clarification, offering limited pricing clarity to investors.

Insights

Securities Analyst

TL;DR: Small insider sale (~0.06 % float) via Form 144; unlikely to materially affect ATHA valuation or liquidity.

This Form 144 signals an intent to sell 25,123 ATHA shares, amounting to only 0.06 % of shares outstanding. The shares stem from a recent restricted-stock vesting, so the motivation likely relates to diversification or tax obligations rather than deteriorating fundamentals. With no past-quarter insider sales and execution routed through a major broker, the transaction should be readily absorbed by daily volume. In my view, the filing is not impactful to the investment thesis but will be monitored by investors tracking insider sentiment.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 38th Fl. New York NY 10004	25123	7374	39042445	07/01/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/30/2025	Restricted Stock Lapse - See Remarks	Athira Pharma, Inc.			108334	07/01/2025	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many Athira Pharma (ATHA) shares are being offered for sale under the Form 144?

The notice covers 25,123 common shares.

What percentage of ATHA’s shares outstanding does the proposed sale represent?

Approximately 0.06 % of the 39,042,445 shares outstanding.

When is the approximate sale date for the ATHA shares?

The filer lists an approximate sale date of 01 July 2025.

Which broker is handling the insider sale of ATHA shares?

The transaction is routed through Morgan Stanley Smith Barney LLC, Executive Financial Services.

How were the shares being sold originally acquired?

They were obtained on 30 Jun 2025 via a Restricted Stock Lapse tied to equity compensation.

On which exchange will the shares be sold?

The filing specifies the NASDAQ stock exchange.